{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"108"},{"groupId":"OG001","value":"124"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"151"},{"groupId":"OG001","value":"153"}],"units":"Participants"}],"description":"participants who died among those randomized to first-line therapy","groups":[{"description":"etopodide, doxorubicin, cisplatin and mitotane\n\nEtoposide\n\nDoxorubicin\n\nCisplatin\n\nMitotane\n\nparticipants who progressed during first line therapy, were eligible to the alternative treatment (Sz-M)","id":"OG000","title":"EDP-M"},{"description":"streptozotocin and mitotane\n\nStreptozotocin\n\nMitotane\n\nparticipants who progressed during first line therapy, were eligible to the alternative treatment (EDP-M)","id":"OG001","title":"Sz-M"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"every 8 weeks until death up to 5 years","title":"Overall Survival","type":"PRIMARY","unitOfMeasure":"participants"}